Bioaccelerate Holdings Inc. today announces that its portfolio company, Innovate Oncology, Inc., New York, and Avantogen Limited, Sydney, Australia and San Diego, CA, have announced execution of a Definitive Agreement whereby Innovate will merge with a wholly-owned subsidiary of Avantogen, thereby acquiring Avantogen's interest in the promising pancreatic chemoresistance inhibitor, RP101.
PrimeZone